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Restoration of a large osteochondral defect
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Abstract
Background: The treatment of articular cartilage defects is a therapeutic challenge for orthopaedic surgeons.
Furthermore, large osteochondral defects needs restoration of the underlying bone for sufficient biomechanical
characteristics as well as the overlying cartilage.
Case presentation: A symptomatic large osteochondral defect in the knee joint was restored using a composite
of umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) 0.5 x 107/ml and 4% hyaluronic acid (HA)
hydrogel. Significant improvements in pain and function of the knee joint were identified by the evaluation at
12 months after surgery. A hyaline-like cartilage completely filled the defect and was congruent with the
surrounding normal cartilage as revealed by magnetic resonance imaging (MRI), a second-look arthroscopy and
histological assessment. The improved clinical outcomes maintained until 5.5 years. MRI also showed the
maintenance of the restored bony and cartilaginous tissues.
Conclusion: This case report suggests that the composite of allogeneic UCB-MSCs and HA hydrogel can be
considered a safe and effective treatment option for large osteochondral defects of the knee.
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Background
The treatment of articular cartilage defects continues to
be one of the most challenging clinical problems for
orthopaedic surgeons. When isolated chondral or osteo-
chondral defects are left untreated, they do not heal and
may progress to symptomatic degeneration of the joint
[1]. Therefore, early surgical intervention for symptom-
atic lesions which are not responding to conservative
treatment is often suggested in an effort to restore nor-
mal joint congruity and pressure distribution, and to
prevent further injury. Therefore, several techniques for
cartilage restoration have been developed [2–4]. Micro-
fracture, osteochondral autograft transfer (OAT) and
autologous chondrocyte implantation (ACI) are the
commonly applied methods, which will be introduced
more in detail below regarding the case of this paper.
The treatment of large osteochondral defects involv-
ing the cartilage as well as the subchondral bone is
more challenging because of two different tissues with
different healing potential [5]. Microfracture, a bone
marrow stimulating arthroscopic technique, seems to
be the most frequently used method to repair small
sized articular cartilage defects (<2 cm2) [6], however, it
is generally not recommended for osteochondral
defects due to limited potential for restoring the under-
lying bony tissue [7]. OAT offers the advantage of
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restoring cartilage tissue as well as subchondral bony
tissue. However, limited graft availability and donor site
morbidity are major limitations [8]. Furthermore, un-
even surface or unstable fixation in multiple grafting
for a large defect is also a concern [9]. Large osteo-
chondral defects can sometimes be treated by ACI,
however ACI is a two-staged procedure and it is hard
to apply the graft in lesions with deep (more than 6 to
8 mm) subchondral defects [10]. ACI is also known to
have very limited potential in restoring bony tissues
and often requires bone grafts for subchondral bone
restoration in cases of large osteochondral defects
[11, 12]. Osteochondral allograft is an another pos-
sible option, but the limited availability of fresh allo-
graft is a major drawback in clinical practice [13].
Therefore, there still lacks an optimal method to re-
store the cartilaginous and bony tissue in a large
osteochondral defect.
Recently, mesenchymal stem cells (MSCs) have be-
come attractive as one of the potential candidates for
cellular therapy, featuring self-renewal, proliferation and
differentiation into mesenchymal tissues, including bone,
tendon, muscle and cartilage [14]. Moreover, MSCs
likely exhibit a capacity of immune-tolerance or im-
mune modulation that may allow allogeneic MSCs
transplantation feasible [15]. There are only two reports
in the literature on the effect of autologous MSCs for
osteochondral defect of the knee [16, 17]. We, however,
could not find a report of allogeneic MSCs transplant-
ation for the restoration of osteochondral defect. In
addition, it was hardly investigated whether MSCs were
effective to treat large osteochondral defect. Umbilical
cord blood-derived MSCs (UCB-MSCs) are ease to
obtain, are non-invasively collected, and have a good
expansible capacity [18, 19]. In addition, some studies
suggest immunomodulatory effects [20, 21]. Therefore,
UCB-MSCs can be an appropriate source for allogeneic
transplantation.
We previously reported that transplanting of UCB-
MSCs and hyaluronic acid hydrogel composite resulted in
favorable cartilage repair in animal models [22–26]. More-
over, recently, we demonstrated that transplantation a
composite of allogeneic UCB-MSCs and HA hydrogel was
safe and effective modality for cartilage repair in osteo-
arthritic knees, which was followed up for more than
7 years without any significant adverse events [27]. In this
paper, we report a first case of transplanting a composite
of allogeneic UCB-MSCs and HA hydrogel in large osteo-
chondral defect.
Case presentation
A 31-year-old female patient was referred to the senior
author after failed conservative treatment of painful right
knee for 7 months. She had no known history of knee
injury. At age 30 years, about 7 months before presenta-
tion to the senior author, the patient began to experience
intermittent right knee pain, popping, giving way and
locking, which was not improved by conservative treat-
ments including medications and physical therapy. On
presentation, the patient had disabling knee pain with
walking at the anterolateral aspect, which was aggra-
vated with ascending or descending stairs. Physical
examination revealed significant lateral joint line ten-
derness with positive McMurray test [28]. She also had
snapping on the lateral compartment on knee motion.
Plain radiographs (Fig. 1) and magnetic resonance im-
aging (MRI) (Fig. 2) revealed a large osteochondral de-
fect of approximately 27 mm × 22 mm in size and
15 mm deep on the lateral femoral condyle with osteo-
chondral loose bodies (x 3). Complex tear of lateral
meniscus was also found. Therefore, in addition to
arthroscopic loose body removal and lateral partial
meniscectomy, the osteochondral lesion should also be
treated. Considering the size and depth of the lesion,
as well as her age, the patient was not a good candidate
for microfracture, OAT or ACI as described above. A
transplantable osteochondral allograft was not avail-
able. Thus, a novel therapeutic option, transplantation
of a composite of UCB-MSCs and HA hydrogel, was
planned in this case. The UCB-MSCs and HA hydrogel
composite was produced by a manufacturing company
(Medipost Inc., Seoul, South Korea) under regulatory
authority approved good manufacturing practice (GMP)
guidelines [22–24]. The UCB-MSCs were isolated and
Fig. 1 a, b Simple radiographic images of a 31-year-old female
showed a large osteochondral defect on the lateral femoral condyle
of right knee
Park et al. BMC Musculoskeletal Disorders  (2017) 18:59 Page 2 of 9
characterized according to previously published methods
[29]. This study was approved by the institutional review
board at our institution. Informed consent was obtained
from patient included in the study.
The patient was taken to the operating room, where
spinal anesthesia was induced. An arthroscopic examin-
ation was performed using a standard anterolateral por-
tal in supine position. After complete inspection of the
joints and assessment of the defects (Fig. 3), a standard
anteromedial portal was made and three osteochondral
loose bodies were removed. Additionally, partial men-
iscectomy was performed for the complex tear of the
lateral meniscus. An arthrotomy through an incision of
approximately 3 cm in length was made through the
anterolateral portal. The osteochondral defect on the
lateral femoral condyle was carefully debrided down to
the bed of the defect with a curette until healthy look-
ing underlying bone appeared. Subsequently, multiple
drilling with a 5 mm diameter drill bit was performed
to the depth of 5 mm for the containment of the com-
posite of UCB-MSCs and HA hydrogel. After the dril-
ling, irrigation was performed to wash out the debris of
bone and cartilage and the lesion site was dried using
suction and gauze for implantation. Finally, the com-
posite of UCB-MSCs 0.5 x 107/ml and 4% HA hydrogel
taken and filled in a 5 mL syringe. Then, the hydrogel
mixture was implanted into the 5 mm drill holes from
the base to the surface by slow injection to avoid any
void (Fig. 4). As the hydrogel is not sticky, the 5 mm
deep drill holes mainly served for the containment of
the implanted MSC-hydrogel mixture. Actually, the
small amount of blood smearing into the hydrogel
seemed to form a clot intermingled with the hydrogel,
thus help maintain the hydrogel in place. After the im-
plantation, the knee was extended carefully with some
retraction of capsular tissues to avoid displacement of
the overlying composite of UCB-MSCs and HA hydro-
gel from the lesion. The wound was closed and a cylin-
der splint was applied. The patient started continuous
passive motion exercises on postoperative day 1 and
was ambulatory with crutches. Non-weight bearing am-
bulation was recommended until 3 months postoperative
and gradually increasing weight bearing as tolerable was
allowed thereafter.
Pain on walking by 100 mm visual analog scale (VAS)
was improved from 46 preoperatively to 8 at postoperative
Fig. 2 Preoperative magnetic resonance image. a Axial, b sagittal and c coronal images showed large osteochondral defect (approximately
2.7 cm × 2.2 cm sized and 1.5 cm deep) on lateral femoral condyle with osteochondral loose body
Fig. 3 a, b Arthroscopic views from the anteromedial portal shows large osteochondral defect on lateral femoral condyle
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1 year. The international knee documentation and com-
mittee (IKDC) subjective score improved from 63.22 pre-
operatively to 85.02 at postoperative 1 year. The Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC) score improved from 25 preoperatively to 2 at
postoperative 1 year. Second look arthroscopy and biopsy
from the implantation site were performed at postopera-
tive 1 year after informed consent. The site of previous
large chondral defect was smooth and fully covered with
hyaline-cartilage like tissue, which was generally firm-to-
hard with excellent peripheral integration (Fig. 5).
There was no area of bone formation or bone exposure
at the articular surface. Biopsy was taken with a biopsy
needle, and histologic evaluation revealed evidence of
hyaline-like cartilage regeneration. Positive Safranin-O
staining was observed throughout the matrix suggesting
the abundant presence of glycosaminoglycan, which is
typical to hyaline cartilage matrix (Fig. 6a). With immu-
nohistochemistry for type I collagen and type II colla-
gen, typical for fibrocartilage and hyaline cartilage,
respectively, weak positivity for type I collagen (Fig. 6b)
and diffuse strong positivity for type II collagen was ob-
served (Fig. 6c). MRI at postoperative 1 year showed
good filling of the defect with abundant repair tissue
and smooth integration to surrounding tissue (Fig. 7a-c).
Moreover, the deep portion of the previous defect corre-
sponding to underlying bone was partially restored as
bony tissue, while the superficial portion near the articular
cartilage was restored as cartilagenous tissue.
The improved scores were maintained until the latest
follow up at 5.5 years postoperatively with VAS 12,
IKDC 85.05 and WOMAC 4. The MRI performed at
5.5 years after surgery showed maintenance of the re-
pair tissue with filling of the defect and integration to
surrounding tissue (Fig. 7d-f ). A delayed gadolinium-
enhanced MRI of the cartilage [30] indicated high gly-
cosaminoglycan content of the regenerated cartilage
(relative ΔR1 index = 1.41, Fig. 8). The restored bony
tissue in the deep portion and the restored cartilage tis-
sue in the superficial portion were maintained without de-
terioration or transition to bony tissue. During follow-up
period, no specific adverse reactions were observed until
5.5 years.
Discussion
We report a case of a successful outcome using the com-
posite of UCB-MSCs 0.5 x 107/ml and 4% HA hydrogel
for the treatment of large and deep osteochondral defect
Fig. 4 Gross photos shows a initial osteochondral defect site, b defect site just after implantation of umbilical cord blood derived mesenchymal
stem cells, and c removed loose bodies
Fig. 5 a, b, c, d Second look arthroscopy shows cartilage repair on lateral femoral condyle at postoperative 1 year
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Fig. 6 Histological findings. a Positive safranin – O staining was observed throughout the matrix. Immunostaining showed b weak staining for
type I collagen but c diffuse strong positivity for type II collagen
Fig. 7 Magnetic resonance image. a, b, c The repair of the osteochondral defect at postoperative 1 year was observed and d, e, f the repaired
tissue was maintained for 5.5 years without deterioration
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of the knee. The clinical results at 1 year and at 5.5 years
postoperatively suggest that this method can be a viable
option in restoring large and deep osteochondral defects.
To our knowledge, this is the first report of a successful
treatment of large osteochondral defect of a human joint
by application of allogeneic MSCs-based product.
Over the past decade, clinical and basic research has
provided the foundation for successful treatment of focal
cartilage defects [31, 32]. The main approaches currently
used in clinical practice are microfracture, OAT, and
ACI. Microfracture and OAT are generally known that
they not recommended for large lesions [33, 34]. ACI
was the first cell therapy used clinically to treat cartilage
defects [35]. ACI has undergone several improvements
over time [36, 37]. However, there are still several short-
comings even with the newly developed ACI techniques;
the main shortcoming is an age-related chondrocyte de-
differentiation during the expansion phase [38]. Chon-
drocyte is known to dedifferentiate to a fibroblast-like
state during cultivation in monolayers. The dedifferenti-
ation represents both morphological changes and alter-
ations in collagen expression patterns, which negatively
affects the potential of the implanted cells to restore the
cartilage tissue. In addition, ACI requires autologous
bone implant for the restoration of the subchondral
bone in large osteochondral defects [11, 12].
To overcome the limitation and shortcomings of
currently available options, a novel option seems to be
required for the treatment of large osteochondral le-
sion of the knee. In this regard, the use of MSCs can
be a potential therapeutic option for the restoration of
cartilage as well as bone in the osteochondral defects,
considering the MSCs’ capacity of self-renewal, multi-
lineage differentiation potential and immunomodula-
tion [39]. Several studies reported that MSCs with
scaffold can repair osteochondral defects in animal
models [40–43]. We have already experienced success-
ful restoration of osteochondral defects with no im-
munologic problem after transplantation of human
UCB-MSCs in an animal model which was a xenograft
model [22–26]. Also, we had seen the safety and effi-
cacy of UCB-MSCs for the restoration of articular car-
tilage defect in seven osteoarthritic patients in phase
1/2 clinical trial performed at our institution [27].
Therefore, we tried to extend the novel approach to
the restoration of subchondral bone as well as the ar-
ticular cartilage in large osteochondral defect case, and
the result was encouraging without any significant ad-
verse events.
To our knowledge, this is the first case report of the
transplantation of allogeneic MSCs for the restoration of
large osteochondral defects of the human knee. In the
literature, there have been only two previous studies
which used autologous MSCs or mixed cell concentrate
containing MSC for the treatment of osteochondral de-
fect of the human knee [16, 17]. A case report of one
patient with a 1-year follow-up presented that the restor-
ation of articular cartilage and subchondral bone for an
osteochondral defect was promoted by implantation of
autologous bone marrow (BM)-MSCs embedded in cal-
cium hydroxyapatite ceramic with interconnected pores
[16]. The technique required two-stage surgery and inva-
sive BM collection. The other study with a 2-year
follow-up described the use of BM aspirate concentrate
(BMAC), a mixture of heterogeneous cell populations,
embedded in hyaluronan based scaffold for osteochon-
dral defects of the knee in 20 patients [17]. Clinical out-
comes were improved and MRI showed bone and
cartilage growth, nearly complete defect filling and satis-
factory integration with surrounding tissue in 80% of
patients at 1 year. Histological staining showed the pres-
ence of proteoglycan, particularly in the middle and deep
zone. Unfortunately, the images of immunohistochemi-
cal staining for type 1 and type 2 collagen were not pro-
vided. Although this technique was one-stage surgery, it
also required invasive BM aspiration for cell collection.
In addition, heterogeneous cell populations had been
used in this study. The MSCs are known to be present
in less than 0.1% of BM aspirate concentrates [44]. Thus
it is difficult to determine whether the bone and cartil-
age repair was by the MSCs or other components, such
as platelet derived growth factors, and consistent results
could not be expected. Moreover, these two related pre-
vious reports lacked longer term follow-up to evaluate
whether the restored tissues were maintained and pro-
vided reliable and durable clinical outcomes. We believe
the results of the case in the current report warrant
Fig. 8 a The change in quantitative R1 in regenerated cartilage and
in native cartilage were obtained at the marked areas to calculate
the relative R1 index, which equals 1.0 in the case of perfect
regeneration. b Higher T1 values (marked in blue) were associated
with increased relative GAG content, which was observed in
regenerated cartilage
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further investigations on the application of allogeneic
MSCs for the restoration of osteochondral defects.
In this case report, the improvements in pain and
function at 1-year post-transplantation were maintained
for 5.5 years. At the latest clinic visit of 5.5 years postop-
eratively, she had returned to full activity without any
limitation as a nurse in a local hospital. In MRI and
second-look arthroscopy at postoperative 1 year, no
overgrowth, delamination or fibrous degeneration at the
site of newly formed tissue were observed, which is often
observed after ACI [45]. In addition, MRI at 5.5 years
after surgery showed the maintenance of restored sub-
chondral bone as well as the overlying articular cartilage
with excellent peripheral integration. We think that the
restoration of subchondral bone which provide a sound
biomechanical environment for the restored defect site
as well as the restoration of good quality cartilage should
have contributed to the observed durable improvement
in pain and function. The result of this case suggests
that the transplantation of the composite of UCB-MSCs
and HA will be an effective therapeutic option for the
treatment of large osteochondral defects of the knee.
There was no adverse effect for 5.5 years. No abnor-
mal findings suggesting rejection, foreign body reaction,
or differentiation towards other mesenchymal lineage
was observed. UCB-MSCs showed low immunogenicity
and immunomodulatory activity [46, 47]. Other in vivo
studies using UCB-MSCs have shown no immune rejec-
tion [22, 23, 25]. One recent study reported that UCB-
MSCs transplanted cells disappeared at 4–8 weeks [48],
which may contribute to the safety of transplantation of
allogeneic UCB-MSCs in this case.
Some limitations of this study needs to be addressed.
First, allogeneic MSCs transplantation might induce an
immune reaction. However, the UCB-MSCs show low
immunogenicity, and have immunomodulatory activity
[47, 49]. In addition, previous in vivo studies using UCB-
MSCs have not shown an immune rejection [22–24, 27].
In this study, there was no adverse reaction resulting
from the rejection response. Second, the lateral menisc-
ectomy and removal of intra-articular osteochondral
loose bodies have also contributed for the improvement
of the pain and function of the patient. However, we be-
lieve that the improvement could have not been that
much as in this case without repair of the large and deep
osteochondral defect. Third, meniscal loss (especially at
the lateral compartment) has been considered as the
contraindication of cell-based cartilage repair. However,
we demonstrated that transplantation a composite of
allogeneic UCB-MSCs and HA hydrogel was safe and ef-
fective modality for cartilage repair in osteoarthritic
knees in which meniscal loss was combined, which was
maintained more than 7 years without deterioration or
significant adverse events [27]. Therefore, we believe
that transplantation of the composite of UCB-MSCs and
HA hydrogel is an appropriate modality for cartilage re-
pair even though patients have an meniscal problem.
Fourth, we could not rule out the effect of HA in the
restoration of the osteochondral defect, although the
HA hydrogel was used for delivering the MSCS and
holding the MSCs in place. However, we learned from
the preclinical studies using HA hydrogel with or with-
out UCB-MSCs that the role of HA hydrogel in restor-
ing the articular cartilage defect had been limited and
the composite of UCB-MSCs and HA hydrogel showed
consistently better results [22, 24]. Fifth, with the result
of this case, we cannot tell whether the result of UCB-
MSCs transplantation is better than ACI-collagen or
matrix-associated ACI [50]. However, considering the
fact that the integrity of the subchondral bone is import-
ant for a long term integrity of the overlying articular
cartilage due to the biomechanical environment issue
[51, 52], we believe that the novel option we report here
will be more suitable than ACI or its modifications. Fi-
nally, this case may need an even longer term outcome.
Conclusion
The results of this study showed that the transplantation
of the composite of UCB-MSCs and HA hydrogel can be
a viable therapeutic option for the restoration of large
osteochondral defects of the human joint. It can be per-
formed through a one-stage arthroscopy assisted surgery
with a small arthrotomy. The result of this case report
warrants further studies on this novel therapeutic option.
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